BioNTech SE - Asset Resilience Ratio

Latest as of March 2026: 22.30%

BioNTech SE (22UA) has an Asset Resilience Ratio of 22.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BioNTech SE working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€4.70 Billion

≈ $5.49 Billion USD Cash + Short-term Investments

Total Assets

€21.07 Billion

≈ $24.64 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how BioNTech SE's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BioNTech SE assets under control.

Liquid Assets Composition Over Time

This chart breaks down BioNTech SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BioNTech SE (22UA) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€4.70 Billion	22.3%
Total Liquid Assets	€4.70 Billion	22.30%

Asset Resilience Insights

Good Liquidity Position: BioNTech SE maintains a healthy 22.30% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

BioNTech SE Industry Peers by Asset Resilience Ratio

Compare BioNTech SE's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for BioNTech SE (2016–2025)

The table below shows the annual Asset Resilience Ratio data for BioNTech SE.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	32.75%	€7.20 Billion ≈ $8.42 Billion	€21.99 Billion ≈ $25.71 Billion	+1.59pp
2024-12-31	31.17%	€7.02 Billion ≈ $8.21 Billion	€22.53 Billion ≈ $26.34 Billion	+9.93pp
2023-12-31	21.23%	€4.89 Billion ≈ $5.71 Billion	€23.01 Billion ≈ $26.90 Billion	+20.42pp
2022-12-31	0.81%	€189.40 Million ≈ $221.43 Million	€23.28 Billion ≈ $27.22 Billion	-1.60pp
2021-12-31	2.41%	€381.60 Million ≈ $446.13 Million	€15.83 Billion ≈ $18.51 Billion	-3.51pp
2020-12-31	5.92%	€137.23 Million ≈ $160.44 Million	€2.32 Billion ≈ $2.71 Billion	+5.71pp
2019-12-31	0.21%	€1.68 Million ≈ $1.96 Million	€797.65 Million ≈ $932.53 Million	+0.16pp
2018-12-31	0.05%	€336.00K ≈ $392.82K	€652.99 Million ≈ $763.41 Million	-0.01pp
2017-12-31	0.07%	€246.00K ≈ $287.60K	€374.71 Million ≈ $438.08 Million	-0.33pp
2016-12-31	0.39%	€1.53 Million ≈ $1.79 Million	€389.96 Million ≈ $455.90 Million	--

pp = percentage points

About BioNTech SE

F:22UA Germany Biotechnology

Market Cap

$24.79 Billion

€21.20 Billion EUR

Market Cap Rank

#1277 Global

#286 in Germany

Share Price

€83.85

Change (1 day)

-3.12%

52-Week Range

€72.05 - €102.20

All Time High

€377.00